Search Within

Alexander Edward Drilon

Formats
  1. Meeting Abstract (374)
  2. Journal Article (224)
  3. Review (23)
  4. Editorial (6)
  5. Correspondence (3)
  6. Book Section (2)
  7. Research Letter (2)
  8. Book Whole (1)
  9. Guidelines (1)
  10. Miscellaneous (1)
Groups
  1. Department of Medicine (637)
  2. Solid Tumor Oncology Division (637)
  3. Thoracic Oncology (637)
  4. Department of Pathology and Laboratory Medicine (208)
  5. GSK Faculty (189)
  6. Human Oncology and Pathogenesis Program (158)

More Groups

People
  1. Marc Ladanyi (122)
  2. Mark Kris (90)
  3. Maria Arcila (82)
  4. David Hyman (78)
  5. Bob Li (65)
  6. Charles Rudin (64)

More People

Years
  1. 2025 (21)
  2. 2024 (61)
  3. 2023 (68)
  4. 2022 (85)
  5. 2021 (76)
  6. 2020 (81)

More Years

Publications
  1. Journal of Clinical Oncology (138)
  2. Annals of Oncology (94)
  3. Journal of Thoracic Oncology (85)
  4. Clinical Cancer Research (31)
  5. JCO Precision Oncology (24)
  6. Cancer Research (23)

More Publications

Publishers
  1. American Society of Clinical Oncology (164)
  2. Elsevier Inc. (119)
  3. Oxford University Press (113)
  4. American Association for Cancer Research (78)
  5. Nature Publishing Group (27)
  6. S. Karger AG (23)

More Publishers

Results (637)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • ROS1-dependent cancers - Biology, diagnostics and therapeutics
    Review

    Drilon, A.; Jenkins, C.; Iyer, S.; Schoenfeld, A.; Keddy, C.; Davare, M. A.
    Nature Reviews Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Genomic characterization of a RET inhibitor–resistant RET fusion–positive lung cancer by CSF cell-free DNA hybrid capture–based sequencing
    Journal Article

    Choudhury, N. J.; Yang, S. R.; Arcila, M.; Mohanty, A. S.; Boire, A.; Drilon, A.
    JCO Precision Oncology (2020)

    Fulltext@MSK | Save
  • A phase II basket study of MCLA-128, a bispecific antibody targeting the HER3 pathway, in NRG1 fusion-positive advanced solid tumors
    Meeting Abstract

    Schram, A. M.; Drilon, A. E.; Macarulla, T.; O'Reilly, E. M.; Rodon, J.; Wolpin, B. M.; Ou, S. H. I.; Kim, D. W.; Yang, J. C.; Lam, J. Y. C.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Growth modulation index (GMI) as a comparative efficacy measure of larotrectinib versus prior systemic treatments for TRK fusion cancer patients
    Meeting Abstract

    Italiano, A.; Hong, D. S.; Briggs, A.; Garcia-Foncillas, J.; Lassen, U. N.; Vassal, G.; Kummar, S.; Van Tilburg, C. M.; Keating, K. N.; Reeves, J. A.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • TRIDENT-1: A global, multicenter, open-label Phase II study investigating the activity of repotrectinib in advanced solid tumors harboring ROS1 or NTRK1-3 rearrangements
    Meeting Abstract

    Doebele, R. C.; Lin, J. J.; Nagasaka, M.; Zhu, V. W.; Gabrail, N. Y.; Bazhenova, L.; Anderson, P. M.; Solomon, B. J.; Dudek, A. Z.; Pippas, A. W.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Kinase fusions drive endocrine resistance in estrogen receptor-positive breast cancer
    Meeting Abstract

    Liu, B.; Ross, D. S.; Schram, A. M.; Razavi, P.; Lagana, S. M.; Zhang, Y.; Scaltriti, M.; Bromberg, J. F.; Ladanyi, M.; Hyman, D. M.; more...
    Cancer Research (2020)

    Fulltext@MSK | Save
  • Efficacy and safety of larotrectinib in patients with cancer and NTRK gene fusions or other alterations
    Meeting Abstract

    Hong, D. S.; Dowlati, A.; Burris, H.; Chu, E.; Brose, M. S.; Farago, A. F.; van Tilburg, C. M.; Kummar, S.; Mascarenhas, L.; Reeves, J. A.; more...
    Cancer Research (2020)

    Fulltext@MSK | Save
  • TRK xDFG mutations trigger a sensitivity switch from type I to II kinase inhibitors
    Meeting Abstract

    Cocco, E.; Lee, J. E.; Kannan, S.; Schram, A. M.; Won, H. H.; Shifman, S.; Kulick, A.; Baldino, L.; Toska, E.; Arena, S.; more...
    Cancer Research (2020)

    Fulltext@MSK | Save
  • Neurotrophic tyrosine receptor kinase (NTRK) gene fusion testing in clinical trials of larotrectinib
    Meeting Abstract

    Rudzinski, E.; Hong, D.; Rudolph, M.; Lockwood, C.; Reeves, J.; Moh, A.; Nogai, H.; Laetsch, T.; Drilon, A.
    Journal of Molecular Diagnostics (2020)

    Fulltext@MSK | Save
  • Decade in review: A new era for RET-rearranged lung cancers
    Review

    Choudhury, N. J.; Drilon, A.
    Translational Lung Cancer Research (2020)

    Fulltext@MSK | Save